Join us for a virtual KOL event featuring Stewart J. Tepper, MD (Geisel School of Medicine at Dartmouth University) and Andrew M. Blumenfeld, MD (Director, The Los Angeles Headache Center) who will discuss the past, present, and potential future treatment landscapes for migraine, along with AEON Biopharma’s unique use of botulinum toxin as a potential therapy.

The event will highlight the difference between monotherapy and combination therapy in the context of migraine treatments. Additionally, AEON Biopharma’s leadership team will provide an update on its clinical programs and the projected timelines for future product development.

A live question and answer session will follow the formal presentations.